Teva has unveiled an expanded innovative-medicines strategy targeting $6–7 billion in annual revenue by 2030, supported by seven late-stage pipeline assets, potential annual launches and a broader R&D investment programme.

Flagship Pioneering has formed Etcelera by combining three biotechnology platforms with AI capabilities to develop a causal-intelligence approach to drug discovery.